Product
CHF10067
Aliases
CHF10067 high dose, CHF10067 intermediate dose, CHF10067 starting dose
1 clinical trial
1 indication
Indication
Idiopathic Pulmonary FibrosisClinical trial
PhIb, Randomised, Double-blind, Placebo-controlled Study to Investigate the Safety, Tolerability, and PK of an i.v. mAb After Single Ascending Doses in Subjects Affected by Idiopathic Pulmonary Fibrosis.Status: Active (not recruiting), Estimated PCD: 2024-06-25